The Role of Imatinib in Pediatric Type 1 Diabetes

Kristen Lavelle; Chester Chamberlain; Michael German; Mark Anderson; Angel Nip; Stephen E Gitelman

doi:10.1210/jcemcr/luae065

The Role of Imatinib in Pediatric Type 1 Diabetes

JCEM Case Rep. 2024 May 3;2(5):luae065. doi: 10.1210/jcemcr/luae065. eCollection 2024 May.

Authors

Kristen Lavelle^{1

2

3}, Chester Chamberlain^{2

3}, Michael German^{1

2

3}, Mark Anderson^{1

3}, Angel Nip⁴, Stephen E Gitelman^{3

4}

Affiliations

¹ Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, CA 94143, USA.
² Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143, USA.
³ Diabetes Center, University of California, San Francisco, CA 94143, USA.
⁴ Department of Pediatrics, Division of Endocrinology, University of California, San Francisco, CA 94143, USA.

Abstract

We report the first case of imatinib use in an adolescent with diabetes and suggest that it impacts the natural course of disease. A 14-year-old male patient presented in diabetic ketoacidosis (DKA) and was diagnosed with presumed autoantibody-negative type 1 diabetes (T1D) as well as myeloid neoplasm with platelet-derived growth factor receptor beta (PDGFRB) rearrangement. After starting exogenous insulin and imatinib, he experienced a 1.7-point reduction in glycated hemoglobin (HbA1c) and a 71% reduction in insulin requirement with sustained partial diabetes remission. Our case suggests imatinib as a potential therapeutic agent for pediatric T1D.

Keywords: case report; diabetes; imatinib; pediatric.

Published by Oxford University Press on behalf of the Endocrine Society 2024.

Publication types

Case Reports